Pralsetinib and selpercatinib, which are highly selective rearranged during transfection (RET) inhibitors, have been approved by the FDA for the treatment of metastatic RET fusion-positive non-small cell lung cancer, advanced RET-mutant medullary thyroid cancer, and advanced RET fusion-positive thyroid cancer (Kim et al., 2021; Duke et al., 2023; Bradford et al., 2021; Wright, 2020). This evidence concerns the gene RET and medullary thyroid gland carcinoma.